Table. Clinical Characteristics, Numbers of Genetic Alterations and Drugs Mentioned in F1 and G360 Reports, and Concordance Between Reports From F1 and G360 Testing.
| Patient Characteristic | All Mutations Reported by at Least 1 Platform (n = 112) |
Mutations Detectable by Both Platforms (n = 45) |
Drugs Recommended by at Least 1 Platform (n = 36) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient No./Sex | Tumor Type | Stage | Time Difference, mo | F1 or G360, No. | Both, No. (%) | F1, No. | Both, No. (%) |
F1, No. | G360, No. | F1 or G360, No. | F1 and G360, No. (%) |
F1, No. | G360, No. |
| 1/F | Breast cancer | IV | 0.5 | 13 | 7 (54) | 6 | 1/7 (14) | 1 | 5 | 2 | 0 | 2 | 0 |
| 2/F | Pancreatic cancer | IV | 1 | 16 | 4 (25) | 12 | 1/4 (25) | 3 | 0 | 2 | 0 | 2 | 0 |
| 3/F | Breast cancer | IV | 15 | 8 | 5 (63) | 3 | 0 | 2 | 3 | 2 | 0 | 0 | 2 |
| 4/F | Thymic carcinoma | I | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5/F | Breast cancer | IV | 0 | 9 | 5 (56) | 4 | 2/5 (40) | 1 | 2 | 7 | 4/7 (57) | 2 | 1 |
| 6/F | Breast cancer | IV | 0.5 | 19 | 4 (21) | 15 | 0 | 2 | 2 | 3 | 0 | 2 | 1 |
| 7/M | Lung cancer | IV | 1 | 18 | 7 (39) | 11 | 1/7 (14) | 1 | 5 | 11 | 1/11 (9) | 1 | 9a |
| 8/M | Salivary gland cancer | IV | 2.5 | 10 | 2 (20) | 8 | 2 (100) | 0 | 0 | 2 | 0 | 2 | 0 |
| 9/F | Breast cancer | III | 0 | 19 | 11 (58) | 8 | 3/11 (27) | 3 | 5 | 7 | 4/7 (57) | 0 | 3 |
| Total | 112 | 45 (40) | 67b | 10/45 (22) | 13 | 22 | 36 | 9/36 (25) | 11 | 16 | |||
Abbreviations: F1, FoundationOne; G360, Guardant360.
a
A recommendation of other KIT proto-oncogene receptor tyrosine kinase inhibitors was counted as a single drug.
b
The 67 alterations detectable owing to technical differences only by F1 testing were excluded from the analysis to avoid an exaggerated portrayal of discordance.